A293780 Stock Overview
A biopharmaceutical company, develops platform based drugs for intractable diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AptaBio Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,260.00 |
| 52 Week High | ₩15,490.00 |
| 52 Week Low | ₩4,930.00 |
| Beta | 2 |
| 1 Month Change | -4.72% |
| 3 Month Change | -20.76% |
| 1 Year Change | -30.83% |
| 3 Year Change | -83.17% |
| 5 Year Change | -62.00% |
| Change since IPO | -67.81% |
Recent News & Updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Recent updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01
Shareholder Returns
| A293780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.6% | -2.3% | -1.9% |
| 1Y | -30.8% | 14.9% | -9.5% |
Return vs Industry: A293780 underperformed the KR Biotechs industry which returned 14.9% over the past year.
Return vs Market: A293780 underperformed the KR Market which returned -9.5% over the past year.
Price Volatility
| A293780 volatility | |
|---|---|
| A293780 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A293780 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A293780's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 32 | Jin Soo | www.aptabio.com |
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells.
AptaBio Therapeutics Inc. Fundamentals Summary
| A293780 fundamental statistics | |
|---|---|
| Market cap | ₩168.28b |
| Earnings (TTM) | -₩20.17b |
| Revenue (TTM) | ₩2.91b |
57.9x
P/S Ratio-8.3x
P/E RatioIs A293780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A293780 income statement (TTM) | |
|---|---|
| Revenue | ₩2.91b |
| Cost of Revenue | ₩2.68b |
| Gross Profit | ₩226.00m |
| Other Expenses | ₩20.40b |
| Earnings | -₩20.17b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -750.33 |
| Gross Margin | 7.78% |
| Net Profit Margin | -694.04% |
| Debt/Equity Ratio | 27.3% |
How did A293780 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:59 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AptaBio Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taehee Kim | Mirae Asset Securities Co., Ltd. |
| Keunhee Seo | Samsung Securities Co. Ltd. |